



Volume 5, Issue 3
March 2026

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E_z - MINUTES

Drugs (and Supplies) Added to the VA National Formulary WITHOUT Prior Authorization

- Aminolevulinic acid oral
- Aminolevulinic acid topical
- Barium sulfate
- CRRT Fluids (including Duosol, NxStage, Phoxillum, Priskasate, Priskasol, and others)
- Ethiodized oil
- Icodextrin 7.5% with electrolytes
- Iodine tincture topical
- Isosulfan blue
- MNEXSPIKE (COVID19 Vaccine, mRNA inj,susp)
- NUVAXOVID (COVID19 Vaccine, Adjuvanted inj,susp)
- Sincalide

Drugs (and Supplies) Added to the VA National Formulary WITH Prior Authorization

- Collagenase clostridium histolyticum 0.9mg/vial inj,lyphl

Drugs (and Supplies) Kept on the VA National Formulary WITH Prior Authorization, MODIFIED RESTRICTIONS

- Dofetilide cap, oral (TIKOSYN) – CFU archived; keep PA-F with restriction to cardiology or locally designated expert

Drugs (and Supplies) Not Added to the VA National Formulary

- Afamitresgene autoleucel (TECELRA)
- Axatilimab-csfr inj, soln (NIKTIMVO)
- Celecoxib (VYSCOXIA) – new oral suspension dosage form; oral caps remain on VANF
- Denosumab-desu (JUBEREQ) inj, soln – biosimilar to XGEVA
- Eturetidigene autotemcel (WASKYRA)
- Octreotide acetate (BYNFEZIA PEN) – considered bioequivalent to Sandostatin, which is on VANF
- Omidenedipag isopropyl 0.002% ophthalmic sol (OMLONTI)
- Onasemnogene abeparvovec-brve (ITVISMA)
- Oral Semaglutide tab (WEGOVY)
- Plozasiran (REDEMPLO) inj, soln
- Revumenib tab (REVUFORJ)
- Thiotepa inj, soln (TEPYLUTE) – FDA-approved based on efficacy findings for thiotepa (TEPADINE), which is on VANF
- Trofinetide (DAYBUE STIX)
- Zanidatamab-hrii inj (ZIHARA)

Formulary Drugs (and Supplies) with Prior Authorization Removed

- None

Drugs (and Supplies) Removed from the VA National Formulary

- None

Updated Criteria for Use

- Acalabrutinib CALQUENCE Criteria Rev Mar 2026
- Ibrutinib IMBRUVICA Criteria Rev Mar 2026
- Zanubrutinib BRUKINSA Criteria Rev Mar 2026
- Guselkumab TREMFYA in Crohn's Disease Criteria Rev Mar 2026
- Guselkumab TREMFYA in Ulcerative Colitis Criteria Rev Mar 2026